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Abstract
A safer and more effective anti-Tuberculosis vaccine is still an urgent need. We probed the
effects of monosodium urate crystals (MSU) on innate immunity to improve the Bacille Calm-
ette-Guerin (BCG) vaccination. Results showed that in vitroMSU cause an enduring macro-
phage stimulation of the anti-mycobacterial response, measured as intracellular killing, ROS
production and phagolysosomematuration. The contribution of MSU to anti-mycobacterial
activity was also shown in vivo. Mice vaccinated in the presence of MSU showed a lower
number of BCG in lymph nodes draining the vaccine inoculation site, in comparison to mice
vaccinated without MSU. Lastly, we showed that MSU improved the efficacy of BCG vaccina-
tion in mice infected withMycobacterium tuberculosis (MTB), measured in terms of lung and
spleen MTB burden. These results demonstrate that the use of MSU as adjuvant may repre-
sent a novel strategy to enhance the efficacy of BCG vaccination.
Introduction
The most recent report fromWHO estimates 8.8 million new incident Tuberculosis (TB) cases
worldwide and 1.3 million deaths [1], making TB one of the most deadly human infectious dis-
ease. The only currently licensed vaccine for TB is the Bacille Calmette-Guerin (BCG), an at-
tenuated strain ofM. bovis, which confers acceptable efficacy against disseminated forms of
childhood TB, but highly variable and largely inadequate protection against the much more
prevalent adult pulmonary TB [2]. Moreover, the fact that high proportions of HIV infected in-
dividuals live in TB endemic regions poses a significant risk when it comes to BCG (or other
live) vaccine, given that the majority of serious complications following BCG administration
occur in immunocompromised patients [3]. In this context, the generation of a safer and more
efficacious BCG-based anti-TB vaccine may require the association of BCG with novel
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immunomodulators or adjuvants aimed at improving its intracellular killing by host phago-
cytes without affecting its efficacy as a vaccine.
Endogenous adjuvants are molecules released following tissue damage and have the capabil-
ity to activate immune response by acting as danger associated molecular patterns (DAMPs)
[4]. Among these molecules, monosodium urate crystals (MSU) are released from locally dam-
aged cells and provide an adjuvant signal that alerts the immune system to danger [5]. Uric
acid is a natural product of the catabolism of the purines that can generate crystals, and form
precipitates of its sodium salt when it reaches supersaturation levels in body fluids [6]. In this
context, deposition of MSU in joints can cause gout, an inflammatory disease characterized by
joint swelling, due to infiltration of neutrophils [7]. Moreover, MSU may promote reactive oxy-
gen species (ROS) generation [8] and NADPH oxidase (NOX) dependent neutrophil extracel-
lular trap formation [9] as well as the release of proinflammatory cytokines [10]. Finally, MSU
mediates the immunostimulatory effects of alum adjuvants by promoting inflammatory den-
dritic cell activation and antigen specific CD4 T [11] and CD8+ T [5] cell response, suggesting
its potential use as endogenous adjuvant for novel vaccine formulations. On these grounds, the
present study reports evidences showing the capability of MSU to induce in vitro a persisting
innate anti-mycobacterial activation, which was associated in vivo with a better efficacy of BCG
vaccination.
Materials and Methods
Bacteria and cell cultures
BCG Pasteur (TMC1011) andMycobacterium tuberculosis (MTB) Erdman (TMC107) were
grown and titred, as described [12]. Human pro-monocytic THP-1 leukemia cell line was
grown as described [12], and induced to differentiate by 72 hour stimulation with 20 ng/ml
Phorbol 12-Myristate 13-Acetate (PMA).
Infection and quantification of mycobacteria
Differentiated THP-1 (dTHP-1) cells, used at the density of 5x105/well, were exposed for 3
hours to BCG at the MOI (multiplicity of infection) of 1 in 24 well plates. After removal of
extra-cellular bacilli, cells were stimulated or not with MSU (Enzo Life Sciences Inc.) at the
concentration of 0.5, 5, 50 μg/ml and colony forming unit (CFU) assays were performed at day
3 and 5 post-infection, as previously described [12]. In several experiments, any possible effects,
induced by MSU on phagocytosis, were evaluated by CFU assay performed on dTHP-1 cells
after 3-hour exposure with BCG, administrated at the MOI of 1 in the presence or absence of
0.05, 0.5, 5 μg/ml MSU. In order to ascertain whether phagolysosome maturation and ROS
generation were responsible for intracellular mycobacterial killing, 10 μM chloroquine, 20 mM
NH4Cl or 100 U/ml poly-ethileneglycol (PEG)-catalase were added to BCG infected cells to-
gether with 5 μMMSU, as described [12].
In order to assess whether MSU could induce a persisting state of activation defined as
“trained immunity” [13], non-differentiated dividing THP-1 cells, used as a model of human
monocytes, were cultured with or without 5 or 50 μg/ml MSU for 3 days and then washed to re-
move the MSU stimulus. After further 4 days of culture, the cells were infected with BCG at the
MOI of 10 for 3 hours. Thereafter, extracellular bacilli were removed by washing (T0) and cells
were cultured for further 3 days (T3), in the presence or absence of 10 μM chloroquine. Intra-
cellular mycobacteria were enumerated by CFU assay, as described [12].
Finally, in order to exclude any possible interference of MSU crystals with BCG viability,
CFU assay was performed in BCG suspended in 200 μl of PBS containing or not 200 μg MSU
crystals after 24 and 48 hours incubation at 37°C.
Improvement of BCG Vaccine by MSU
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Fluorimetric analysis
Intracellular Ca2+ was measured after labeling cells with the 3 μM fluorescent intracellular Ca2+
indicator Fluo-3/AM (Molecular Probes, NL), as described [12], followed by incubation at
37°C with 5 μg/ml MSU, for the times indicated in the figures. In several experiments, 20 μM
BAPTA-AM (Sigma, MO), 3 mM ethylene glycol tetra-acetic acid (EGTA, Calbiochem, San
Diego, CA) were added 30 minutes and 15 minutes before MSU addition, respectively. Intracel-
lular Ca2+ was determined by fluorimetric analysis using 406 nm for excitation and 526 nm
for emission.
ROS generation was analysed by loading cells with 10 μM of the fluorescent indicator
20,70-dichlorofluorescein diacetate (DCF, Molecular Probe) for 60 min at 37°C in the dark.
Thereafter, cells were washed twice, stimulated for 20 minutes with 5 μg/ml MSU. ROS genera-
tion was determined by fluorimetric analysis using 488 nm for excitation and 530 nm for emis-
sion. In several experiments, in order to ascertain the role of Ca++ in ROS generation, either
20 μM BAPTA-AM (Sigma, MO) or 3 mM ethylene glycol tetra-acetic acid (EGTA, Calbio-
chem, San Diego, CA) were added 30 minutes or 15 minutes before MSU addition, respectively.
As control, DCF labeled cells were treated with PEG-catalase 100U/ml for 30 minutes at 37°C
and then stimulated for 20 minutes with 5 μg/ml MSU crystals.
Intraphagosomal acidification of vacuoles containing BCG was monitored by using BCG
labelled with 100 μg/ml of the pH sensitive dye N-hydroxysuccin-imidyl 5-(and 6-)-carboxy-
fluorescein (NHS-CF) (Sigma), as described [14]; in particular, dTHP-1 cells were infected with
NHS labelled BCG for 3 hours at the MOI of 5 and then stimulated overnight with 5 μg/ml of
MSU. Intraphagosomal acidification was determined as a decrease of fluorescence intensity, mea-
sured at an excitation wavelength of 492 nm and emission wavelength of 517 nm.
Intracellular pH was determined in dTHP-1 cells infected with BCG for 3 hours at the MOI
of 5, stimulated overnight with 5 μg/ml of MSU and then labelled with Lysosensor Green DN
189, as described [15]. Phagosomal acidification was determined by fluorescence intensity
measured at an excitation wavelength of 443 nm and emission wavelength of 505 nm. The role
of phagosomal maturation in the intraphagolysosomal pH was assessed by culturing cells in
the presence of 10 μM chloroquine.
Proteolitic activity of dTHP-1 cells infected or not with BCG for 3 hours and stimulated
or not overnight with 5 μg/ml of MSU was analysed by incubating cells with DQ-Red BSA
(10 μg/ml, Molecular Probes) for 2 hours at 37°C. Proteolitic activity was then measured as
fluorescence intensity measured at an excitation wavelength of 590 nm and emission wave-
length of 620 nm.
All fluorimetric analysis were performed by the use of a Perkin Elmer LS50B luminescence
spectrometer.
Confocal microscopy analysis
The degree of maturation of endosomes containing BCG was assessed on BCG infected dTHP-
1 cells stimulated for 18 hours with 5 μg/ml MSU, by analyzing the co-localization of bacilli
with lysosomes after staining the mycobacteria with auramine and the lysosomes with Alexa
Fluor 647 anti-LAMP-3 monoclonal antibody (IgG1, clone MX-49.129.5, Santa Cruz Biotech-
nology, Inc.), as described [12].
IL-1β determination
The levels of IL-1β production in the supernatant were measured by a human IL-1β ELISA kit
(Life Technologies), used according to the manufacturer’s instruction.
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Mice vaccination and MTB challenge
C57BL/6 female mice (Harlan) fed commercial mouse chow and water ad libitum and kept
under pathogen-free conditions and used in accordance with institutional guidelines in com-
pliance with national and international law and policies. All animal experiments were autho-
rized by the Ethical Committee of the Università Cattolica del Sacro Cuore (permit number:
Q21 462(A.290b)/C.E.Sp.An./2009). All efforts were made to minimize suffering; all manipula-
tions were performed under medetomidine/ketamine anesthesia and mice were sacrificed by
cervical dislocation after anesthesia. Five mice per group (matched for sex and age between 8
and 10 weeks) were vaccinated with i) 106 CFU of BCG suspended in 200 μl PBS, ii) 106 BCG
suspended in 200 μl PBS containing 200 μg MSU crystals, or iii) 200 μl PBS alone, via subcuta-
neous route. The amount of MSU used in vivo has been chosen on the basis of adjuvant activity
reported in previous studies [16–17].
To assess BCG persistence in vivo, the draining lymph nodes were removed aseptically and
homogenized in 5 ml of 0.05% Tween80-PBS by using Seward Stomacher 80 blender (Tekmar,
Cincinnati, OH). The homogenates were diluted serially in the Tween-80-PBS solution, and
50 μl aliquots were plated on Milddlebrook 7H11 agar (Difco, Detroit, MI). The number of
CFU was determined after 20 days of incubation at 37°C in sealed plastic bags.
Ten weeks following immunization, vaccinated and control mice were infected aerogeni-
cally with 100 CFU/mouse ofM. tuberculosis Erdman by using a Milddlebrook chamber
(Glas-Col, Terre Haute, IN), as previously described [18]. The vaccinated and control mice
were sacrificed 28 days after challenge, and bacterial colonization of lung and spleen tissues
was assessed, as described [18].
Statistical analysis
Statistical analysis was carried out by Graphpad Prism 3.0 software package. Comparison be-
tween groups was done using Student’s t test. p< 0.05 was considered statistically significant.
Results
MSU promote innate anti-mycobacterial response in human
macrophages
The pro-inflammatory effect of MSU [6], their capability to promote antigen presentation [11]
and to drive T cell differentiation and polarization [19] have been previously documented, but
data suggesting their possible effects in activating anti-mycobacterial innate immunity are not
available. In this context, dTHP-1 cells infected with BCG at the MOI of 1 were stimulated
with MSU and intracellular mycobacterial viability was evaluated by CFU assay. Results show a
significant reduction of intracellular BCG colonies, at day 5 after infection, at all doses of MSU
used, with a peak in the reduction observed with 5 μg/ml of MSU (Fig 1A). In addition, when
the infection was performed in the presence of 0.5 and 5 μg/ml MSU we showed a significant
increase of BCG phagocytosis measured after 3 hours from mycobacterial exposure (Fig 1B).
MSU induce Ca2+ mediated ROS generation
Intracellular calcium increase is required for many different signal transduction pathways, in-
cluding activation of anti-mycobacterial responses [20, 21]. We therefore analyzed cytosolic
Ca2+ influx in dTHP-1 cells following stimulation with MSU. Results show that cytosolic Ca2+
concentration peaks 10 minutes after MSU stimulation and remains almost constant up to the
later time points (Fig 2A). The addition to the culture of EGTA and BAPTA-AM, an extracel-
lular and intracellular Ca2+ chelator, respectively, caused a complete abrogation of cytosolic
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Ca2+ influx (inset of Fig 2B). Moreover, as Ca2+ is required for the assembly and activation of
the superoxide-generating NADPH oxidase complex [22], we tested ROS generation and its
possible dependence by Ca2+. Results show that MSU induce production of ROS, which are al-
most abrogated in the presence of EGTA and BAPTA-AM (Fig 2B), and in the presence of cat-
alase (S1 Fig).
Fig 1. MSU crystals enhance antimycobacterial activity. (A) Differentiated THP-1 (dTHP1) cells were
infected with BCG at the MOI of 1 and then stimulated or not with 0.5, 5, 50 μg/ml of MSU for 3 and 5 days.
The results are expressed as means ± Standard Deviation (SD) of CFU values performed in triplicate and are
representative of three independent experiments. * p 0.001 in comparison with non-stimulated control
cells. (B) Stimulation of human macrophages with MSU enhances phagocytosis of BCG. Differentiated THP-
1 cells were exposed to BCG at the MOI of 1 for 3 hour in the presence or not of 0.05, 0.5, 5 μg/ml MSU.
Results are expressed as mean ± SD of CFU values performed in triplicate and are representative of two
independent experiments. * p < 0.05 in comparison with non-stimulated control cells.
doi:10.1371/journal.pone.0127279.g001
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MSU promote phagolysosome maturation
To evaluate the maturation status of the phagosomes, we monitored phagosomal acidification
by labelling BCG with N-hydroxysuccinimide (NHS)-carboxyfluorescein, a pH sensitive fluo-
rochrome [15]. Results show that MSU promote acidification of phagosomes containing BCG
and that this effect was significantly reverted, even if not completely, by the addition of cholor-
oquine (Fig 3A), a lysosomotropic compound inhibiting phagolysosome acidification [12]. A
quantitative analysis of intracellular pH demonstrated that MSU reduce intracellular pH both
in BCG uninfected and infected macrophages and this effect was almost completely reverted in
BCG infected macrophages by the addition of chloroquine, suggesting a phagolysosome driven
Fig 2. MSU crystals enhance Ca2+ dependent ROS production. (A) dTHP-1 cells were incubated with
3 μM Fluo-3/AM at 37°C for 1 hour in the dark and were stimulated with 5 μg/ml MSU. After stimulation,
fluorescence emission was continuously monitored for 30 minutes and expressed as to determine relative
alteration in intensity. (B) dTHP-1 cells were incubated for 1 hour at the dark with 10 μMDCF, or with 3 μM
Fluo-3/AM (inset of the figure), and were stimulated with 5 μg/ml MSU. Ca2+ dependence ROS generation
was assessed by adding 20 μMBAPTA-AM or 3 mM EGTA 30 minutes and 15 minutes before MSU addition,
respectively. Fluorescence emission was monitored at 20 minutes after stimulation. Results are expressed
as mean ± SD of arbitrary fluorescence units performed in triplicate and are representative of three separate
experiments. * p < 0.01 in comparison with non-stimulated control cells
doi:10.1371/journal.pone.0127279.g002
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process of intracellular acidification (Fig 3B). As phagolysosome acidification and maturation
is associated with proteolitic enzyme activation, we monitored phagosomal protease activation
by DQ-BSA staining [12]. Results show that MSU promote phagosome maturation and prote-
olysis activation in both BCG infected and uninfected macrophages (Fig 3C). Phagolysosome
maturation was also analyzed by confocal microscopy in terms of co-localization of BCG with
LAMP-3+ vacuoles. Results show that the stimulation with MSU significantly increased the co-
localization of BCG with LAMP-3+ compartments in comparison to un-stimulated BCG in-
fected control cells (Fig 3D and 3E).
MSU reduce intracellular BCG growth by a phagolysosome mediated
and ROS dependent mechanism
Phagocytes generate ROS by using superoxide-generating NADPH oxidase (NOX) family pro-
teins, which plays pivotal roles in host defence against bacterial and fungal pathogens [23], and
whose polymerization occurs on maturing phagosomes [24]. Following overnight stimulation
with MSU, a significant increase in ROS production was observed in both BCG infected and
uninfected dTHP-1 cells in comparison with un-stimulated cells (Fig 4). Moreover, chloro-
quine addition inhibited 76% and 40% of ROS generation induced by MSU in BCG-infected
and-uninfected dTHP-1 cells (p< 0.001), respectively, indicating that most of ROS production
is of phagolysosomal origin during BCG infection.
In order to assess the role of phagolysosome maturation and ROS production in intracellu-
lar mycobacterial killing induced by MSU, dTHP-1 cells were infected with BCG, stimulated
with MSU and then exposed to the lysosomotropic agents chloroquine or NH4Cl which both
increase intralysosomal pH and are considered general lysosomal inhibitors. Results show that
the anti-mycobacterial activity increased by MSU was mediated by phagolysosome maturation
and acidification since the addition of chloroquine or NH4Cl upon MSU treatment significant-
ly increased intracellular mycobacterial viability to values closed to control cells (Fig 5A).
Moreover, to assess the role of ROS in the MSU induced intracellular mycobacterial killing,
BCG-infected cells were exposed to PEG-Catalase (PEG-Cat). The results indicate that PEG-
Cat abolishes MSU crystal induced intracellular mycobacterial killing (Fig 5B).
MSU induce trained anti-mycobacterial innate immunity
A functional reprogramming of monocytes leading to a trained innate immunity has been re-
cently reported following infection with Candida albicans or stimulation with TLR-4 ligands
such as β-glucan [13]. On these ground, we wondered whether the antimicrobial activity in-
duced by MSU could persist over time following stimulation of non differentiated, dividing
THP-1 cells, used as a model of human monocytes. To this aim, THP-1 cells were stimulated
according to the protocol shown in Fig 6A and infected 7 days after MSU stimulation. Intracel-
lular mycobacterial growth was evaluated in terms of CFU obtained immediately after 3 hour
mycobacterial exposure (T0) and after 3 days of infection. Results show a significant dose-de-
pendent decrease of intracellular mycobacterial growth following pre-stimulation of monocytes
with MSU (Fig 6B), suggesting the capability of MSU to generate an enduring anti-mycobacte-
rial activity. Moreover, treatment of BCG infected THP-1 pre-stimulated or not with MSU and
then treated with chloroquine, a drug known to arrest phagolysosome maturation, caused
higher mycobacterial CFU counts than unstimulated THP-1, suggesting that phagolysosome
maturation is required for both MSU induced and basal intracellular mycobacterial killing
(Fig 6C). Finally, the increase in antimycobacterial activity was associated with a significant in-
crease of IL-1β production in cells pre-stimulated with either 5 or 50 μg/ml MSU.
Improvement of BCG Vaccine by MSU
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Fig 3. MSU crystals promotematuration of phagosomes containing BCG. (A) dTHP-1 cells were infected with NHS labelled BCG at theMOI of 1 and then
stimulated overnight with 5 μg/ml of MSU, in the presence or absence 10 μMChloroquine. Results are expressed in terms of mean ± SD of arbitrary fluorescence
units of triplicate values and are representative of two independent experiments. * p < 0.001 in comparison with non-stimulated control cells, ° p < 0.001 in
comparison with MSU stimulated cells. (B) dTHP-1 cells were infected with BCG, stimulated overnight with 5 μg/ml of MSU, in the presence or absence of 10 μM
Chloroquine (Cq), and then labelled with 1 μMLysosensor green DND 189. Results are expressed asmean ± SD of pH values from cultures performed in
triplicate and are representative of two independent experiments. * p < 0.001 in comparison with non-stimulated control cells, ° p < 0.001 in comparison with
BCG infected MSU stimulated cells (C) Protease activity of BCG infected dTHP-1 cells stimulated overnight with 5 μg/ml of MSU was analysed by loading of
10 μg/ml DQ red BSA for 2h at 37°C. Results are expressed asmean ± SD of triplicate values and are representative of three independent experiments.
* p 0.01 in comparison with non-stimulated control cells. (D) Confocal microscopy representative images out of 10 per condition showing the increase of
Auramine-stained BCG (green) residing in LAMP-3 positive vacuoles (red) after stimulation with 5 μg/ml of MSU. One representative experiment out of three is
shown. (E) Summary of themean percentage ± standard deviation (SD) of BCG co-localizing in LAMP-3-positive vacuoles determined by acquiring at least 10
images per condition and by counting 50 dTHP-1 cells per sample, after stimulation or not with MSU. Three different experiments were assessed. * p < 0.05 in
comparison with BCG-infected cells (data were analyzed using the unpaired Student’s t-test).
doi:10.1371/journal.pone.0127279.g003
Improvement of BCG Vaccine by MSU
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The co-administration of BCG and MSU enhances the efficacy of BCG
vaccination in a mouse model
BCG is a live attenuated vaccine with debatable efficacy, but considered safe since rarely its ad-
ministration is associated to severe adverse events. As a live attenuated vaccine, however, BCG
is not recommended in immunocompromised patients, such as HIV+ individuals [25]. The ca-
pability of MSU to activate and train innate anti-mycobacterial response prompted us to test
their possible use as adjuvants in a novel BCG-based vaccine formulation in order to increase
both the efficacy of anti-TB vaccination and the clearance of BCG after inoculation in order to
reduce the risks of BCGitis in immunocompromised patients. As a measure of clearance, in a
first series of experiments, BCG was inoculated in mice in the presence or absence of MSU and
15 days later, mycobacterial CFU were enumerated in the lymph nodes draining the inocula-
tion site. Results (Fig 7A) showed that the association of MSU to BCG causes a significant in
vivo killing of BCG, measured as a significant reduction of BCG CFU in draining lymph nodes.
In this context, any direct modification on BCG viability was not observed by the presence of
MSU in the novel vaccine formulation (S2 Fig). To test the efficacy of BCG vaccination in asso-
ciation to MSU as adjuvants we used a mouse model of aerosolic infection with MTB [18].
Briefly, naïve mice or mice vaccinated with BCG or with BCG/MSU were aerogenically infected
with MTB 10 weeks after the immunization. Mice were euthanized 4 weeks after infection and
both lungs and spleens were removed for the analysis of mycobacterial burden. Results show
that MTB colonies both in the lungs and in the spleens (Fig 7B and 7C, respectively) were sig-
nificantly reduced in mice vaccinated with BCG and MSU in comparison to mice vaccinated
with BCG alone.
Discussion
BCG actually represents the sole anti-TB immuno-prophylactic tool available for vaccination
of neonates and individuals at increased risk of MTB infection. It is a live vaccine with docu-
mented protecting activity against systemic forms of TB in childhood [26], but its protective ef-
fect against pulmonary disease in childhood is variable and there is no evidence for protective
Fig 4. MSU crystals induce phagolysosome dependent ROS generation. dTHP-1 cells were infected or
not with BCG at the MOI of 5 and then labelled with 10 μMDCF for 60min. Thereafter, cells were washed twice,
stimulated or not overnight with 5 μg/ml MSU in the presence or absence of 10 μMChloroquine (Cq). Results
are expressed as means ± SD of arbitrary fluorescence units of triplicate values and are representative of two
independent experiments. * p < 0.001 in comparison with non-stimulated control cells. ° p < 0.001 in
comparison with MSU stimulated cells or with MSU-stimulated BCG-infected cells.
doi:10.1371/journal.pone.0127279.g004
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effects in HIV infected children [26]. Moreover, WHO stopped to recommending live, attenu-
ated, BCG vaccination at birth for asymptomatic HIV infected infants, even where there is a
risk of TB exposure early in life, due to high risk of disseminated BCG disease [26]. These evi-
dences claim the need for a safer, and possibly more efficient, anti-TB vaccine, replacing or im-
proving the already available BCG vaccine [27]. In this context, out of 14 anti-TB vaccine
actually in clinical pipeline, 5 are indicated for HIV infected patients and consist mainly of
viral vector or subunit vaccines [28–29]. In the present study, we have evaluated the possibility
to improve the existing vaccine by associating BCG with MSU aiming at increasing its clear-
ance after administration to reduce the risks of BCGitis and without reducing or even improv-
ing its efficacy.
Precipitation of MSU in individuals with hyperuricemia causes Gout symptomatology by
inducing a strong acute inflammatory response in joints and bursal tissues [30]. Acute inflam-
matory reaction induced by MSU involves the activation of the inflammasome NLRP3 as well
Fig 5. MSU crystals reduce intracellular BCG viability in a phagolysosomematuration dependent and
ROSmediatedmanner. BCG infected dTHP-1 cells were stimulated or not with 5 μg/ml MSU and CFU
assays were performed at day 3 post-infection. (A) In order to ascertain whether phagolysosome maturation
was responsible for intracellular mycobacterial killing, 10 μM chloroquine (Cq) or 20 mM NH4Cl was added to
BCG-infected cells together with MSU. Results are expressed as mean ± SD of CFU values performed in
triplicate and are representative of two independent experiments. * p < 0.001 in comparison with non-
stimulated control cells. (B) In order to ascertain the role of ROS in intracellular mycobacterial killing, 100 U/
ml PEG-catalase was added to BCG infected cells together with MSU. Results are expressed as mean ± SD
of CFU values performed in triplicate and are representative of two independent experiments. * p < 0.001 in
comparison with non-stimulated control cells.
doi:10.1371/journal.pone.0127279.g005
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as IL-1β and IL-18 production [31], which in turn mediates the expansion of the pro-inflam-
matory T helper 17 cells [19]. In the present study, we have demonstrated on the one hand the
inefficacy of MSU to directly affect BCG viability and, on the other hand, the capability of
Fig 6. MSU crystals induce trained anti-mycobacterial innate immunity. (A) Diagram showing the course
of in vitro preincubation experiment. THP-1 cells were cultured with 5 or 50 μg/ml MSU for 3 days. Thereafter,
the medium was changed to remove MSU stimulus and cells cultured for further 4 days. Finally, cells were
exposed to BCG at the MOI of 10 for 3 hours (T0), washed and cultured for further 3 days (T3). (B)
Intracellular mycobacterial growth was monitored in BCG infected THP-1 cells prestimulated or not with 5 or
50 μg/ml MSU. Results are shown as mean ± SD of CFU values performed in triplicate and are representative
of three independent experiments. ° p < 0.05 and * p < 0.001 in comparison with same time non pre-
stimulated control cells. (C) Intracellular mycobacterial growth was monitored in THP-1 cells, pre-stimulated
or not with 50 μg/ml MSU, and exposed or not to 10 μM chloroquine after BCG infection for 3 days. Results
are shown as mean ° SD of CFU values performed in triplicate. * p < 0.05 and ° p < 0.01 in comparison with
same time non pre-stimulated control cells. (D) IL-1β production in the supernatant of BCG infected THP-1
cells pre-stimulated or not with either 5 or 50 μg/ml MSU. Results are shown as mean ± SD of values
performed in triplicate and are representative of three independent experiments. * p < 0.05 in comparison
with same time non pre-stimulated control cells.
doi:10.1371/journal.pone.0127279.g006
Improvement of BCG Vaccine by MSU
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MSU to enhance phagocytosis and induce restriction of intracellular BCG growth, so adding to
its intrinsic and well-known pro-inflammatory properties the capability to increase antimicro-
bial innate immune response. Unexpectedly, the effects in macrophages appeared to be inverse-
ly correlated to the dose of MSU used, with an effect, in terms of CFU reduction, higher at
5 μg/ml than at 50 μg/ml. These results can reflect different modes of interaction of MSU with
cell membrane, depending by the dose used. In this context, low amounts of MSU may directly
interact with CD14/TLR2/TLR4 systems to enhance microbicidal response, whereas higher
amounts may induce lipid sorting on cell membrane to form more optimized interactions with
solid surfaces, and allowing phagocytosis but not the activation of mycobacteriocidal signal
transduction pathways [32].
Fig 7. Co-administration of BCGwith MSU crystals enhances the clearance and efficacy of BCG
vaccination. Five mice per group were vaccinated with i) 106 CFU BCG, ii) 106 CFU BCG+MSU [200 μg], or
iii) PBS alone. (A) Mice were sacrificed after 15 days from immunization and BCG colonies enumerated by
the draining axillary lymph nodes. Immunized and control mice were infected 10 weeks post immunization
withM. tuberculosis Erdman ( 100 CFU/mouse) by the aerogenic route. Twenty-eight days later, mice were
sacrificed and bacterial loads were determined by CFU counting in the lungs (B) and spleens (C). * p < 0.05
in comparison with BCG vaccinated mice.
doi:10.1371/journal.pone.0127279.g007
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Ca2+ is a ubiquitous second messenger that controls multiple processes in phagocytes, in-
cluding the activation of microbicidal mechanisms and it is required for phagolysosome matu-
ration [12] and the assembly and activation of superoxide–generating NADPH oxidase
complex [22]. Intracellular Ca2+ elevation was observed in neutrophil following stimulation
with inflammatory amounts of MSU [33]. Our results show that MSU induce cytosolic Ca2+
mobilization and promote Ca2+ mediated ROS generation also in human macrophages.
NADPH oxidase assemblies on maturing phagosomes and ROS generation can be used as a
measure of phagosomal maturation [22]. Moreover, both MTB and BCG are able to inhibit
functional maturation and acidification of phagosomes by preventing fusion with acidic, hy-
drolytic lysosomes [34]. Our results show that MSU induce acidification and maturation of
phagosomes containing BCG, as detected in terms of pH acidification and decrease of pH sen-
sitive NHS fluorescence. In fact, the addition of the lysosomotropic agent chloroquine, which
can be considered as general lysosomal inhibitor [12, 20], in combination with MSU to BCG-
infected cells significantly increases the phagosomal pH, making it similar to that observed in
the absence of MSU. Finally, these processes are necessary for ROS generation and intracellular
mycobacterial killing, as the treatment with Chloroquine or NH4Cl (another general lysosomal
inhibitor) [12,20], significantly reduces ROS and enhances intracellular mycobacterial viability.
A functional reprogramming of human monocytes leading to a form of innate memory has
been recently described [35]. Monocytes treated with Candida albicans [13], BCG [36] or β-
glucan [13] showed enhanced pro-inflammatory cytokine production (such as IL-1 β, TNF-α
and IL-6), which persisted for 1 week after initial stimulation. This form of innate memory was
associated to stable changes in histone trimethylation at H3K4, suggesting the involvement of
epigenetic mechanisms in this phenomenon. Results reported herein show that pre-stimulation
of human monocytes with MSU induced a persistent capability to restrict intracellular BCG
growth, by a phagolysosome maturation dependent mechanism, maintained by cell progeny
up to day 10 from stimulation. Moreover, the increased anti-mycobacterial response observed
in MSU pre-stimulated cells was also associated with a significant increase of IL-1βsecretion,
further suggesting that an epigenetic reprogramming of monocytes is operative in our experi-
mental model. Furthermore, the superior protection, as anti-TB vaccine, induced by BCG
ΔureC::hly over parental BCG has been described to be associated with inflammasome activa-
tion and autophagy [37] and IL-1β has been reported to confer host resistance through the
induction of eicosanoids that limits excessive type 1 interferon production and foster mycobac-
terial containment [38]. On these grounds, immunization strategies targeting these innate im-
mune pathways could represent additional tools for rational design of novel anti-TB vaccines.
The possibility that MSU could be used in vivo as novel endogenous adjuvants has been pre-
viously suggested in murine models of tumor immune rejection [39]. Moreover, the mecha-
nism of action of the well-known adjuvant alum has been recently reported to be dependent, at
least in part, by the local accumulation of MSU [11]. However, it remains a question as to why
alum mediates only antibody responses whereas MSU stimulates a prevalent cell mediated im-
mune response. In this context, future studies may reveal additional regulatory mechanisms
unique to alum that suppress cytolitic T cell induction. Finally, the safety of intradermal injec-
tion of MSU in healthy human volunteers has been reported [40]. Although this latter study
was not characterized as a phase 1 clinical trial, it represents a preliminary study showing ap-
parent absence of MSU toxicity in humans and may provide the basis for future controlled clin-
ical trials. Results reported herein show that MSU when administrated in mice in association to
BCG, significantly reduce BCG colonies in draining lymph nodes, in agreement with their ef-
fects observed in vitro. Although the reduction of BCG viability is considered a contraindica-
tion for the maintenance of a long-lasting protective effect, it may be favored in conditions of
high risk for HIV infection, provided that its efficacy profile is not affected. In this context, our
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results show that mice vaccinated with BCG and MSU show a significant improvement in lung
and spleen MTB burden.
The absence of a clear and unequivocal correlate of protection identified by the T cell im-
mune response against MTB [2] makes it difficult to identify a defined vaccine strategy against
TB, which remains a severe disease both in immunocompetent and in immunocompromised
individuals, such as HIV-infected subjects. In this context, the herein proposed novel formula-
tion BCG and MSU may take advantage by the well-known adjuvant properties of MSU and by
its capability, reported herein, to enhance a persisting anti-mycobacterial response by innate
immune cells.
Supporting Information
S1 Fig. PEG-catalase pre-treatment reduces ROS levels induced by MSU. dTHP-1 cells were
labeled with 10 μMDCF for 60 min. Thereafter, cells were washed twice, stimulated for 20
minutes with 5 μg/ml MSU in the presence or absence of 100 U/ml PEG-catalase (Cat). Results
are expressed as means ± SD of arbitrary fluorescence units of triplicates and are representative
of two independent experiments.  p< 0.05 in comparison with non stimulated control cells,
° p< 0.05 in comparison with MSU stimulated cells.
(TIF)
S2 Fig. Evaluation of BCG stability following formulation with MSU. BCG was suspended
in 200 μl PBS in the presence or absence of 200 μg MSU crystals in order to mimic BCG formu-
lation which was administrated in mice. Mycobacterial viability was monitored by CFU assay
at 24 and 48 hours incubation at 37°C. Data are expressed as mean ± S.D. of CFU values per-
formed in triplicate. n.s. = not significant in comparison with control BCG.
(TIF)
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